Antiretroviral News and Research

RSS

ViiV Healthcare to expand Patient Assistance Program

ViiV Healthcare will expand its Patient Assistance Program effective January 1, 2011 and continue its Patient Savings Card program to help maintain access to HIV medicines for those most affected by the economic downturn in the United States. Specifically, ViiV Healthcare will launch the ViiV Healthcare Patient Assistance Program with an increased maximum household income level for enrollment and is piloting membership in the Welvista program, a nonprofit program to facilitate access to HIV medications for individuals currently on ADAP waiting lists.

13 Oct 2010

Chevron Corporation raises $25 million for Global Fund

Chevron Corporation today announced that it will commit an additional $25 million to The Global Fund to Fight AIDS, Tuberculosis and Malaria, raising its 6-year investment in the organization to $55 million.

6 Oct 2010

FDA grants Matrix tentative approval under PEPFAR for Atazanavir Sulfate Capsules ANDA

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Atazanavir Sulfate Capsules, 150 mg and 300 mg. This product will be eligible for purchase outside the U.S. in certain developing countries.

5 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

GHI won't compromise PEPFAR, Global AIDS Coordinator says at House Foreign Affairs' Committee hearing

During a House Committee on Foreign Affairs' hearing on the future of PEPFAR Wednesday, U.S. Global AIDS Coordinator Ambassador Eric Goosby assured lawmakers that the decision by President Barack Obama to make PEPFAR part of the president's Global Health Initiative (GHI) would not compromise "the widely praised plan," CQ HealthBeat reports.

1 Oct 2010

Antiretroviral therapy does not reduce risk of HIV transmission

For married couples in which one partner is HIV-positive and the other is HIV-negative, antiretroviral therapy (ART) does not reduce the risk of transmitting HIV to the uninfected partner, according to a study from China in the October issue of JAIDS: Journal of Acquired Immune Deficiency Syndromes.

1 Oct 2010

NIH grants for UNC investigators to study HIV/AIDS prevention methods

Investigators at the University of North Carolina at Chapel Hill comprise one of 12 scientific teams in more than a dozen states that will receive National Institutes of Health (NIH) grants to study effective ways to prevent and treat HIV/AIDS among people in the criminal justice system.

30 Sep 2010

UN Secretary announces global strategy for women and children's health at MDG summit

At the UN Millennium Development Goals (MDG) summit in New York this week, world leaders gathered to review progress on the eight goals agreed in 2000 on alleviating world poverty and ill-health by 2015. As the summit came to a close, governments, businesses and aid organisations made commitments totaling $40bn to reach the goals, with particular emphasis on improving maternal and child health.

30 Sep 2010

U.N. agencies' report examines global progress in fight against HIV/AIDS

"A record 1.2 million people in low- and middle-income countries started antiretroviral therapy for HIV/AIDS in 2009" - a 30 percent increase from the previous year and a 13-fold increase in six years, according to a joint report released Tuesday by the WHO, UNICEF and UNAIDS, Reuters reports. In total, the report found that 5.25 million people received antiretroviral therapy (ART) in 2009, three-quarters of them living in Africa (Migiro, 9/28).

30 Sep 2010

Opinions: U.S. aid to Pakistan; MDGS; GHI and Global Fund

The U.S. military has been working hard to provide flood assistance, but most of that is invisible to Pakistanis, David Ignatius writes in a Washington Post opinion piece. The article examines the views of Pakistani flood victims, including criticism of their own government's response.

30 Sep 2010

HIV AIDS drugs’ universal access dream remains improbable: Report

In a disappointing new report jointly commissioned by the World Health Organisation (WHO), the UN's AIDS programme and UNICEF it was revealed that only one third of people worldwide who need life-saving HIV drugs are actually getting treated. Universal access to these medicines has been the theme of effort but it was seen that that targets would not be met. The report urges the poorer countries must “substantially ramp up” the funds for HIV/AIDS.

29 Sep 2010

Significant progress made universally in increasing access to HIV/AIDS services: Report

Significant progress has been made in several low- and middle-income countries in increasing access to HIV/AIDS services, according to a new report released today. The report Towards universal access by WHO, the United Nations Children's Fund and the Joint United Nations Programme on HIV/AIDS is the fourth annual report for tracking progress made in achieving the 2010 target of providing universal access to HIV prevention, treatment and care.

29 Sep 2010

Report shows continuing progress in scaling up global HIV/AIDS interventions

The 2010 report on universal access to HIV prevention, care and treatment released today by WHO, UNAIDS, and UNICEF shows continuing progress in scaling up global HIV/AIDS interventions.

29 Sep 2010

Early initiation of ART may prevent immune system damage in HIV patients: Study

HIV-infected individuals who begin antiretroviral therapy (ART) soon after acquiring the virus may have stronger immune responses to other pathogens than HIV-infected individuals who begin ART later, a new study from the National Institutes of Health has found. This finding suggests that early initiation of ART may prevent irreversible immune system damage and adds to the body of evidence showing significant health benefits from early ART.

29 Sep 2010

NIH awards grants to treat HIV/AIDS in criminal justice system

Twelve scientific teams in more than a dozen states will receive National Institutes of Health (NIH) grants to study effective ways to prevent and treat HIV/AIDS among people in the criminal justice system.

24 Sep 2010

HIV-infected African Americans likely to develop kidney failure: Study

Among African Americans, HIV infection is increasingly recognized as an important risk factor for developing chronic kidney disease. African American men and women are more likely to die from the complications of HIV infection compared with Caucasian men and women.

24 Sep 2010

ARRA's legacies may solve challenges related to health, energy and environment

The presidents of six leading research universities and two higher-education associations joined Vice President Joe Biden and White House science advisor Dr. John Holdren this morning to discuss the scientific research and related activities that have been made possible by the American Recovery and Reinvestment Act (ARRA).

22 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies.

21 Sep 2010

International activists ask: 'Will MDG summit fail HIV-positive people?'

A group of Russian AIDS activists are charging that the Russian Ministry of Health is denying that there are drug stock-outs that prevent patients from starting or continuing treatment. "In this situation, people with HIV face a choice: to die quietly at home or try to attract the attention of the government and the media," said Alexey Yaskovich, a Russian activist from Novgorod. "Therefore, activists will continue to go to the streets of Moscow and hold public events dedicated to saving their lives."

21 Sep 2010